Continue to Site

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

Home » TriReme, founder win AngioScore patent spat, lose bid for legal fees

TriReme, founder win AngioScore patent spat, lose bid for legal fees

By

AngioScore, TriReme Medical, Quattro Vascular, QT Vascular

AngioScore lost the patent infringement portion of its legal war with co-founder and former board member Eitan Konstantino, but won’t have to pay its opponents’ $4.8 million legal tab, a federal judge ruled this week.

AngioScore, which accused Konstantino of violating his fiduciary duties when he started TriReme Medical, Quattro Vascular and QT Vascular, won a $20 million judgment in July that the defendants are appealing. But the patent infringement case, which Judge Yvonne Gonzalez Rogers of the U.S. District Court for Northern California split from the suit in March, went the other way after a jury returned a verdict Sept. 29 of non-infringement and invalidity.

TriReme and its co-defendants in October asked Gonzalez Rogers to order AngioScore to cough up $4.8 million to cover its legal costs. AngioScore’s infringement theories were “exceptionally meritless,” they argued, according to court documents.

Citing an email from AngioScore CEO Tom Trotter, the defendants argued that AngioScore’s intent with the patent infringement case was to disrupt a potential acquisition.

“In fact, in an e-mail sent only weeks before AngioScore filed its complaint for patent infringement, AngioScore’s CEO, Tom Trotter, confirmed that the lawsuit was intended to disrupt investment in or acquisition of Defendants by a company that his subordinate thought might be interested in TriReme: ‘If so, they may be in for a big surprise when they move toward a close and find TriReme is facing a potential major lawsuit,'” they argued, according to the documents. “Mr. Trotter also boasted to AngioScore’s sales team: “They [Defendants] will soon be hearing from us.”

But Gonzalez Rogers found nothing “inherently suspect” in Trotter’s comments.

“A CEO might make such a remark regarding a suit brought in good faith,” she wrote.

“The court finds that the totality of the circumstances at issue here does not suggest the patent suit was brought in bad faith, with an improper purpose, or in the absence of an adequate pre-filing investigation. Defendants have put forth no authority supporting an exceptional case finding in such a context,” Gonzalez Rogers wrote.

In case you missed it

RSS From Medical Design & Outsourcing

  • Johnson & Johnson MedTech plans manufacturing facility in Costa Rica
    Johnson & Johnson MedTech will build a 200,000-sf² manufacturing facility in Alajuela, Costa Rica, the medical device developer said today. It’s the largest investment J&J MedTech has ever made outside the U.S., according to Procomer, the agency that promotes Costa Rican exports. J&J MedTech — Johnson & Johnson’s medical device business — said the plant… […]
  • The secret behind Intuitive’s surgical robotics success
    Intuitive Surgical has pioneered robotic surgery since the 1990s, continuously driving innovation and collaboration through data to advance patient care. Teamwork between surgeons and engineers has been a crucial factor behind Intuitive developing effective surgical platforms that solve real-world problems that surgeons face. Multibillion-dollar companies including Medtronic and Johnson & Johnson — and smaller up-and-comers… […]
  • 3D-printed ventricles made from fiber-infused gel ink mimic heartbeats
    Researchers have found a way to use fiber-infused ink to 3D-print a functional heart ventricle that mimics the beating of a human heart. The team included researchers from Harvard John A. Paulson School of Engineering and Applied Sciences (SEAS) and the Wyss Institute for Biologically Inspired Engineering at Harvard University. They reported on their new… […]
  • Synchron’s plan to beat Neuralink in the neuroprosthetic BCI race
    Competing brain-computer interface (BCI) developers Synchron and Neuralink both announced big news this month as they move their dueling neuroimplant technologies forward. The device developers each have FDA investigational device exemption (IDE) for their experimental BCIs. They’ve also got billionaires backing their R&D and regulatory efforts, with Neuralink owned by Elon Musk and Synchron funded… […]
  • How LimFlow’s foot-saving system prevents amputations in patients with no other options
    LimFlow’s breakthrough system for treating chronic limb-threatening ischemia (CLTI) is the first of its kind approved by the FDA for this severe form of peripheral artery disease (PAD). For CLTI patients who have lost blood flow below their knee and have no other suitable endovascular or surgical treatment options available, the LimFlow System for Transcatheter… […]
  • Device strategies to prevent healthcare-associated infections
    Device design, sterilization before use and proper cleaning of reusable equipment can prevent infections and save lives. By Ted Eveleth, AvantGuard Nosocomial infections, also commonly known as healthcare-associated infections (HAIs), are a multibillion-dollar problem and a leading cause of morbidity and mortality around the world. On any given day, about 1 in 31 hospital patients… […]
  • MGS breaks ground on innovation and tech center
    MGS has started construction of its new innovation center at its headquarters campus in Germantown, Wisconsin. The medtech contract manufacturer said the 120,000 ft² facility is scheduled to open by the end of 2024. The MGS expansion will have collaborative workspaces dedicated to ideation and product development, tooling development, automation, and part and process validation,… […]
  • Two-armed surgical robot prototype targets pediatric brain tumors
    Researchers say they’ve developed a surgical robot for removing brain tumors in children, and that it could also offer a less invasive, safer option for adult neurosurgery and other procedures. The trick is using hollow, nitinol robot arms to allow neurosurgeons to swap tools during a tumor resection procedure, said Pierre DuPont. He’s the chief… […]
  • S3 Connected Health joins DiMe’s International Regulatory Pathways project
    NEWS RELEASE: S3 Connected Health joins DiMe’s team of digital health experts in their new project ‘International Regulatory Pathways’ DUBLIN, September 19, 2023 – Building on the success of the Digital Health US Regulatory Pathways, DiMe has assembled a global team of digital health experts, including S3 Connected Health, to support digital health product developers… […]
  • Four steps medtech startups can’t put off
    Developing and commercializing a new medical device is a success worth toasting for medtech startups — but that success also makes it more likely that litigation is in their future. There are steps medtech startups can take to protect themselves down the road, said Greenberg Traurig shareholder Ginger Pigott, a litigator who defends major medical… […]
  • How Biosense Webster aims to expand access to AFib care
    Electrophysiology is “an incredibly vibrant space,” said Nikki Sidi, but access remains a challenge. Nikki Sidi, the U.S. president of Johnson & Johnson’s Biosense Webster, can look at her own company as one of those paving the way in electrophysiology (EP). Its recent milestones include multiple atrial fibrillation (AFib) mapping catheters, including ablation and mapping devices. … […]

Copyright © 2023 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy